Targeted alternative splicing: a common therapeutic platform to treat inherited diseases. Wilton, Fletcher, Zheng, Mastaglia. 2018-2020 $798,165. NHMRC Application 114479.1

Stargardt disease. Chen, de Roach, Hunt and Wilton. 2018-2019 $120,000. Macular Disease Foundation.

Sarepta Therapeutics Contract Research (US$1,405,350) “Correlation study: PMO relative activity ranking in DMD patient myoblasts and normal myoblasts”.

NHMRC European Union ($989,884) “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”.

MDA USA (US$300,000) “Oligomer design & validation for DMD: quantum improvements in exon skipping”.

NHMRC ($439,000) “Optimization of splice switching therapies to treat Duchenne muscular dystrophy”. Bellgard MI, Wilton SD, Fletcher S.

NHMRC ($575,558) “The L-type calcium as a reporter of successful morpholino oligomer therapy in treatment of Duchenne muscular dystrophy cardiomyopathy”. Hool L, Fletcher S, Wilton SD.